Business Context and Reporting Period
The supplied filing is Immudyne, Inc.’s unaudited Form 10-Q for the quarter and nine months ended September 30, 2017—not a LifeMD, Inc. filing as indicated in the request metadata. Immudyne develops and sells yeast beta glucan immune-support ingredients and finished cosmetic products; its majority-owned subsidiary markets hair-care and skincare products.
Financial Results and Liquidity
| Metric | Q3 2017 | Q3 2016 | Nine months 2017 | Nine months 2016 |
|---|---|---|---|---|
| Net sales | $2.052 million | $1.384 million | $3.584 million | $4.253 million |
| Gross profit (margin) | $1.516 million (74%) | $0.996 million (72%) | $2.515 million (70%) | $2.984 million (70%) |
| Operating loss | $0.274 million | $0.208 million | $0.874 million | $0.466 million |
| Net loss | $0.652 million | $0.218 million | $1.028 million | $0.482 million |
| Net loss attributable to Immudyne | $0.679 million | $0.227 million | $0.986 million | $0.489 million |
| Operating cash flow | Not separately provided for the quarter | $(0.316) million | $(0.112) million |
At September 30, cash was $562,760; current assets were $1.337 million and current liabilities $776,984, yielding reported working capital of $560,467 and a 1.72 current ratio. Inventory was $377,800, up from $160,270 at year-end 2016. Notes payable were $77,333; the company reported approximately $60,000 of remaining availability under its American Express working-capital line. Nine-month financing cash flow was $695,888, and cash increased by $380,199.
Material Changes Versus the Prior Comparable Period
- Third-quarter sales rose 48% year over year, led by finished cosmetic products, up about 54%; management attributed growth to direct marketing and the launch of in-licensed hair-loss products.
- Nine-month sales fell 16%, as finished cosmetic product sales declined about 25% during a product transition; additives sales increased about 26%.
- Q3 operating expenses rose 49%, mainly from increased marketing. Nine-month operating expenses were down 2%, but the operating loss widened as revenue and gross profit fell.
- Nine-month net loss more than doubled. Interest expense rose to $650,718 from $15,805, principally reflecting financing and debt-settlement costs; the period also included a $634,325 loss on settlement of notes and other payables in the cash-flow reconciliation.
- Comparative 2016 statements were restated to reclassify marketing costs from cost of sales to marketing expense. The filing says the reclassification did not change net income.
Outlook, Risks, and Unusual Items
- Management said additional sales and/or capital would be needed to meet operating and capital requirements for the remainder of 2017. It expected existing operations and prior financing to fund operations through 2017, while warning that additional financing might be required and could not be assured.
- The filing states that accumulated deficit was approximately $10.7 million and operating cash flows were negative, raising substantial doubt about the company’s ability to continue as a going concern.
- On September 21, 2017, shareholders approved an increase in authorized shares. The company said this removed the basis for derivative-liability classification. The nine-month results include a $496,617 fair-value gain, while Q3 includes a $377,213 fair-value loss.
- Shares issued and outstanding increased during the period amid equity sales, service awards, and cashless exercises. Equity financing may dilute shareholders; debt financing would add servicing obligations.
- Disclosure controls and procedures were deemed ineffective. The filing identifies material weaknesses involving segregation of duties, accounting and reporting policies, IT access and disaster recovery, and lack of a written whistleblower policy.
- Risks cited include product regulation, intellectual-property protection, marketing costs, customer concentration, and dependence on continued sales growth and financing. No material legal proceeding was identified by management.
Important Facts for Investors to Verify
- Confirm the issuer identity: this filing is for Immudyne, Inc., not LifeMD, Inc.
- Review the going-concern disclosure, cash needs, available credit, and financing subsequent to September 30, 2017.
- Reconcile the derivative-liability accounting and its fair-value effects across the quarter and nine-month period.
- Assess sales trends by segment, including whether the hair-care launch can sustain growth and offset the nine-month decline.
- Evaluate dilution and potential obligations from outstanding options, warrants, and performance-based awards.
- Monitor remediation of the disclosed material weaknesses and the reliability of future financial reporting.